AltheaDx to take DxS K-RAS test to US study centres
This article was originally published in Clinica
Executive Summary
Oncology diagnostics company AltheaDx is set to provide study centres in the US with a K-RAS mutation test kit developed by UK firm DxS for research purposes. An agreement between the two firms will see San Diego, California-based AltheaDx use the test to support clinical research where cancer patients are assessed for their K-RAS mutation status. Manchester-based DxS said that oncologists can use the technology to study patient response to cancer therapies. The test allows clinicians to screen for mutations in the K-RAS gene which is mutated in approximately 35-45% of metastatic colorectal cancer. Financial terms of the agreement were not revealed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals